Generate Biomedicines

aid: generate-biomedicines
name: Generate Biomedicines
description: Generate Biomedicines is a Somerville, Massachusetts therapeutics company pioneering Generative Biology, a machine-learning-driven
  approach to de novo protein design across antibodies, peptides, enzymes, and gene therapies. Founded out of Flagship Pioneering
  and chaired by Noubar Afeyan, the company trains generative models on the full compendium of natural protein structures
  and sequences plus proprietary wet-lab data to design novel protein therapeutics computationally rather than by trial-and-error
  discovery. Its open-source flagship is Chroma, a programmable diffusion-based generative model for joint protein structure
  and sequence design published in Nature 2023 ("Illuminating protein space with a programmable generative model", doi:10.1038/s41586-023-06728-8)
  and released on GitHub under Apache 2.0 with pretrained weights available under a custom Chroma Parameters License (free
  for academic and nonprofit use). Chroma uses equivariant graph neural networks, diffusion modeling, and conditional random
  fields to sample all-atom protein structures with sub-quadratic complexity, supporting conditional generation via composable
  Conditioner modules for symmetry, substructure, shape, and secondary-structure constraints. The internal Generate Platform
  iterates on a "generate, build, measure, learn" loop that pairs in-silico design with high-throughput protein synthesis
  and characterization; the company reports having generated, built, and tested more than 42,000 proteins. Generate Biomedicines
  has platform collaborations with Amgen (six programs, January 2022) and Novartis (multiple programs, September 2024) and
  a CAR T collaboration with Roswell Park. Its clinical pipeline is led by GB-0895, a long-acting anti-TSLP antibody for severe
  asthma now in Phase 3 (SOLAIRIA study) with a parallel Phase 1 in COPD, plus preclinical programs GB-4362 (anti-free-MMAE
  for ADC oncology safety) and GB-5267 (MUC16 armored CAR T for ovarian cancer). The company priced its initial public offering
  in February 2026. Revenue derives from drug development, partner collaborations, and (for Chroma) commercial weights licensing;
  there is no public developer REST/HTTPS API or SDK for the Generate Platform itself — Chroma is consumed as a Python library
  installed via pip with model weights downloaded from chroma-weights.generatebiomedicines.com after registering for an API
  key.
type: Index
deliveryModel:
  model: library
  open_source: false
  commercial: false
  callable_host: false
  label: Library · distributed through package registries, no callable service
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Producing
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/generate-biomedicines.png
tags:
- Generative Biology
- Protein Design
- De Novo Design
- Diffusion Models
- Antibodies
- Drug Discovery
- Therapeutics
- Machine-Learning
- Biotechnology
- Chroma
- Foundation Models
- Equivariant Neural Networks
- Flagship Pioneering
tags_raw:
- Generative Biology
- Protein Design
- De Novo Design
- Diffusion Models
- Antibodies
- Drug Discovery
- Therapeutics
- Machine Learning
- Biotechnology
- Chroma
- Foundation Models
- Equivariant Neural Networks
- Flagship Pioneering
url: https://raw.githubusercontent.com/api-evangelist/generate-biomedicines/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
  url: security/generate-biomedicines-domain-security.yml
- type: Website
  url: https://generatebiomedicines.com
- type: Portal
  url: https://generatebiomedicines.com
- type: Platform
  url: https://generatebiomedicines.com/platform
- type: GenerativeBiology
  url: https://generatebiomedicines.com/generative-biology
- type: Pipeline
  url: https://generatebiomedicines.com/pipeline
- type: AboutUs
  url: https://generatebiomedicines.com/about-us
- type: Newsroom
  url: https://generatebiomedicines.com/media-center
- type: NewsReleases
  url: https://generatebiomedicines.com/media-center?type=newsReleases
- type: Blog
  url: https://generatebiomedicines.com/media-center?type=blogPosts
- type: MediaHighlights
  url: https://generatebiomedicines.com/media-center?type=mediaHighlights
- type: Investors
  url: https://investors.generatebiomedicines.com
- type: Careers
  url: https://generatebiomedicines.com/careers
- type: Contact
  url: https://generatebiomedicines.com/contact
- type: GitHubOrganization
  url: https://github.com/generatebio
- type: OpenSource
  url: https://github.com/generatebio/chroma
- type: SDKs
  url: https://pypi.org/project/generate-chroma/
  name: Chroma Python package (generate-chroma)
- type: Paper
  url: https://www.nature.com/articles/s41586-023-06728-8
  name: Illuminating protein space with a programmable generative model (Nature, 2023)
- type: ModelWeights
  url: https://chroma-weights.generatebiomedicines.com
- type: LinkedIn
  url: https://www.linkedin.com/company/generate-biomedicines
- type: Twitter
  url: https://twitter.com/generatebio
- type: YouTube
  url: https://www.youtube.com/@generatebiomedicines
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com